Profile data is unavailable for this security.
About the company
MacroGenics, Inc. is a biopharmaceutical company focused on developing and commercializing monoclonal antibody-based therapeutics for the treatment of cancer. It generates its pipeline of product candidates primarily from its suite of antibody-based technology platforms, which have applicability across broad therapeutic domains. It is developing product candidates that target various tumor-associated antigens and immune checkpoint molecules. Its lead pipeline program is vobramitamab duocarmazine (vobra duo), an antibody-drug conjugate (ADC) that targets B7-H3, a molecule in the B7 family of immune regulator proteins that is expressed by several different tumor types. Its clinical pipeline includes two product candidates based on its, bispecific DART technology that co-engages both PD-1 and other checkpoint molecules. These candidates include lorigerlimab and tebotelimab. In addition, it is developing MGD024, a bispecific DART molecule. It is also developing various other programs.
- Revenue in USD (TTM)43.36m
- Net income in USD-23.24m
- Incorporated2000
- Employees339.00
- LocationMacroGenics Inc9704 Medical Center DriveROCKVILLE 20850United StatesUSA
- Phone+1 (301) 251-5172
- Fax+1 (301) 251-5321
- Websitehttps://www.macrogenics.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revance Therapeutics Inc | 236.65m | -313.72m | 278.88m | 534.00 | -- | -- | -- | 1.18 | -3.61 | -3.65 | 2.71 | -0.945 | 0.4482 | 1.87 | 10.46 | -- | -59.42 | -55.55 | -69.02 | -63.20 | 69.11 | -- | -132.57 | -304.96 | 4.64 | -30.79 | 1.30 | -- | 76.55 | 128.84 | 9.10 | -- | -0.3022 | -- |
| ESSA Pharma Inc | 0.00 | -27.73m | 279.49m | 50.00 | -- | 2.09 | -- | -- | -0.6282 | -0.6282 | 0.00 | 3.01 | 0.00 | -- | -- | 0.00 | -18.71 | -23.01 | -19.12 | -23.67 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 24.27 | -- | -- | -- |
| Aquestive Therapeutics Inc | 51.50m | -28.77m | 279.49m | 135.00 | -- | -- | -- | 5.43 | -0.4273 | -0.4273 | 0.7836 | -0.4012 | 0.5398 | 2.78 | 6.49 | 381,496.30 | -30.15 | -76.63 | -43.46 | -123.85 | 60.23 | 64.24 | -55.85 | -102.95 | 5.85 | -3.51 | -- | -- | 6.09 | -5.59 | 85.54 | -- | -11.42 | -- |
| CorMedix Inc | 0.00 | -50.24m | 280.95m | 82.00 | -- | 4.84 | -- | -- | -0.9291 | -0.9291 | 0.00 | 1.06 | 0.00 | -- | -- | 0.00 | -78.96 | -54.84 | -88.88 | -62.32 | -- | 6.18 | -- | -18,323.42 | 6.41 | -- | 0.00 | -- | -100.00 | -- | -56.02 | -- | 46.27 | -- |
| Inozyme Pharma Inc | 0.00 | -77.11m | 282.06m | 59.00 | -- | 2.37 | -- | -- | -1.37 | -1.37 | 0.00 | 1.92 | 0.00 | -- | -- | 0.00 | -48.39 | -45.00 | -52.50 | -48.90 | -- | -- | -- | -- | -- | -- | 0.2748 | -- | -- | -- | -6.13 | -- | 2.85 | -- |
| Inovio Pharmaceuticals Inc | 717.07k | -124.94m | 283.98m | 122.00 | -- | 2.71 | -- | 396.03 | -5.54 | -5.54 | 0.0317 | 4.04 | 0.0036 | -- | 0.5465 | 5,877.62 | -63.15 | -59.52 | -78.79 | -71.29 | -- | -- | -17,423.39 | -4,097.36 | -- | -- | 0.00 | -- | -91.89 | -51.33 | 51.71 | -- | -31.22 | -- |
| Vanda Pharmaceuticals Inc. | 177.60m | -4.89m | 285.75m | 203.00 | -- | 0.5253 | -- | 1.61 | -0.0846 | -0.0846 | 3.08 | 9.35 | 0.2738 | 10.32 | 5.80 | 874,896.60 | -0.7538 | 6.61 | -0.8808 | 7.62 | 92.42 | 90.55 | -2.75 | 15.18 | 4.69 | -- | 0.00 | 0.00 | -24.27 | -0.0496 | -60.02 | -36.96 | -56.77 | -- |
| Poseida Therapeutics Inc | 82.50m | -108.86m | 286.03m | 335.00 | -- | 3.38 | -- | 3.47 | -1.18 | -1.18 | 0.8907 | 0.8739 | 0.2864 | -- | 8.06 | 250,006.10 | -37.78 | -40.70 | -49.17 | -47.72 | -- | -- | -131.94 | -233.49 | -- | -12.88 | 0.4096 | -- | -50.42 | -- | -92.85 | -- | 19.01 | -- |
| Nature's Sunshine Products Inc | 447.68m | 16.54m | 288.44m | 814.00 | 18.16 | 1.88 | 9.67 | 0.6443 | 0.8479 | 0.8479 | 22.96 | 8.20 | 1.86 | 1.91 | 44.39 | 549,974.20 | 7.33 | 6.57 | 10.66 | 9.41 | 72.19 | 72.69 | 3.94 | 3.74 | 1.42 | -- | 0.013 | 27.72 | 5.55 | 4.07 | 3,965.64 | -- | 16.73 | -- |
| Xeris Biopharma Holdings Inc | 171.36m | -64.40m | 289.10m | 377.00 | -- | -- | -- | 1.69 | -0.4648 | -0.4648 | 1.24 | -0.0619 | 0.5209 | 0.838 | 5.02 | 454,525.20 | -19.58 | -43.60 | -25.58 | -56.57 | 82.90 | 78.23 | -37.58 | -143.08 | 1.81 | -2.04 | 1.04 | -- | 48.68 | 131.50 | 34.23 | -- | 8.43 | -- |
| MacroGenics Inc | 43.36m | -23.24m | 289.99m | 339.00 | -- | 2.73 | -- | 6.69 | -0.3754 | -0.3754 | 0.6969 | 1.70 | 0.1465 | 5.13 | 2.00 | 127,896.80 | -7.85 | -37.76 | -9.48 | -45.53 | 84.28 | -- | -53.60 | -133.96 | 3.61 | -96.21 | 0.00 | -- | -61.33 | -0.4606 | 92.44 | -- | -41.13 | -- |
| XOMA Corp | 5.81m | -45.09m | 291.89m | 13.00 | -- | 3.55 | -- | 50.23 | -3.92 | -3.92 | 0.5053 | 7.08 | 0.0329 | -- | 1,291.33 | 447,000.00 | -22.44 | -4.55 | -24.19 | -4.94 | -- | -- | -681.69 | -31.87 | -- | -24.55 | 0.5944 | -- | -21.06 | -2.13 | -105.10 | -- | 23.16 | -- |
| Procaps Group SA | 414.10m | 52.20m | 294.47m | 5.50k | 5.01 | 7.48 | 4.23 | 0.7111 | 0.5209 | 0.5209 | 4.16 | 0.3491 | 0.854 | 1.87 | 3.38 | 75,290.18 | 10.77 | -- | 19.01 | -- | 55.04 | -- | 12.61 | -- | 0.9861 | -- | 0.8829 | -- | 0.0434 | -- | 142.18 | -- | -- | -- |
| Solid Biosciences Inc | 0.00 | -90.25m | 299.74m | 88.00 | -- | 1.40 | -- | -- | -3.94 | -3.94 | 0.00 | 5.57 | 0.00 | -- | -- | 0.00 | -37.74 | -49.99 | -40.68 | -56.25 | -- | -- | -- | -2,117.05 | -- | -- | 0.0075 | -- | -100.00 | -- | -11.67 | -- | -27.90 | -- |
| Mersana Therapeutics Inc | 38.30m | -134.81m | 302.23m | 123.00 | -- | 10.80 | -- | 7.89 | -1.14 | -1.14 | 0.3203 | 0.2287 | 0.1549 | -- | -- | 311,365.80 | -54.52 | -61.68 | -75.37 | -81.35 | -- | -- | -352.01 | -622.19 | -- | -- | 0.4749 | -- | 38.65 | 28.32 | 15.94 | -- | 9.61 | -- |
Data as of May 24 2024. Currency figures normalised to MacroGenics Inc's reporting currency: US Dollar USD
63.86%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Bellevue Asset Management AGas of 31 Mar 2024 | 9.97m | 15.93% |
| Avoro Capital Advisor LLCas of 31 Mar 2024 | 6.15m | 9.83% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 4.79m | 7.66% |
| SSgA Funds Management, Inc.as of 31 Mar 2024 | 4.39m | 7.02% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 3.57m | 5.70% |
| T. Rowe Price Investment Management, Inc.as of 31 Mar 2024 | 2.77m | 4.42% |
| T. Rowe Price Associates, Inc. (Investment Management)as of 31 Mar 2024 | 2.41m | 3.85% |
| Armistice Capital LLCas of 31 Mar 2024 | 2.40m | 3.84% |
| RA Capital Management LPas of 31 Mar 2024 | 2.08m | 3.33% |
| Geode Capital Management LLCas of 31 Mar 2024 | 1.43m | 2.29% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
